Navigation Links
DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Date:9/26/2007

Multinational Trial to Evaluate Safety, Efficacy of Novel Cortisol

Inhibitor

SAN FRANCISCO, Sept. 26 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that it has begun dosing patients in a Phase 2b clinical trial of DIO-902, a novel cortisol synthesis inhibitor being studied for the treatment of type 2 diabetes mellitus (T2DM).

The Phase 2b multinational trial is a randomized, placebo-controlled, double-blinded study designed to evaluate the safety and efficacy of DIO-902 and to determine dosing for pivotal Phase 3 clinical studies. The primary efficacy endpoint being evaluated is the change in HbA1c, a key measurement of glycemic control, compared to placebo. Secondary endpoints include the change in total and LDL-cholesterol, and the change in blood pressure. Top line data from the trial is expected by the second half of 2008.

"The rollout of this multinational, multicenter trial demonstrates DiObex's ability to launch a major clinical program for the treatment of metabolic disease," CEO David Cory said. "With treatments for both type 1 and type 2 diabetes in mid-stage clinical study and additional indications under evaluation for DIO-902, DiObex is well positioned to move a strong pipeline of product candidates into the advanced stages of development."

The trial is being conducted at 20 centers across the United States, Australia and New Zealand. Approximately 200 patients will be treated for 16 weeks. Patients who are already on a stable dose of metformin will be randomized to receive placebo or one of three doses of DIO-902 once daily for 16 weeks, with the option of continuing on an open label extension for an additional six months of treatment.

Preclinical and clinical studies have suggested that a link exists between high cortisol levels and visceral adiposity, insulin resistance, and hyperglycemia -- common elements of T2DM and metabolic syndrome. There are no cortisol synthesis inhibitors on the market today, potentially making DIO-902 a first-in-category treatment.

"We are very encouraged by results of our earlier Phase 2a study that showed a trend toward improved glycemic control, as well as statistically significant reductions in levels of cholesterol and C-reactive protein that suggest DIO-902 could potentially lower the risk of heart disease," said Dr. Bernice Welles, Vice President of Development at DiObex. "DIO-902 could potentially give patients a way to manage their disease with fewer medications and, if ultimately approved, would be a valuable addition to the armamentarium of agents to help patients with type 2 diabetes."

About DIO-902

DIO-902 is a cortisol synthesis inhibitor that is being developed as a therapy for glucose and cholesterol control in patients with T2DM. DIO-902 may also benefit hypercholesterolemia patients who fail to achieve treatment targets on current lipid medications or those who are statin intolerant. DIO-902 increases insulin sensitivity by lowering cortisol levels. The primary mechanism of action is via inhibition of the 11-beta-hydroxylase

enzyme, the terminal step in cortisol synthesis in the adrenal gland. DIO-902 has also been shown to lower total and LDL-cholesterol by inhibiting 14-alpha-demethylase, a key enzyme in cholesterol synthesis. DIO-902 is the levdex enantiomer of ketoconazole. Pre-clinical and clinical evidence are supportive that DIO-902 may be safer and more effective than racemic ketoconazole.

About DiObex

DiObex, Inc. is a San Francisco-based biotechnology company founded to develop novel products for the treatment of metabolic diseases. DiObex has two product candidates in Phase 2 clinical development. DIO-901 (very low dose glucagon) is in development as an extended release subcutaneous formulation for reducing or preventing insulin-induced hypoglycemia in type 1 diabetes mellitus. DIO-901 has received Fast Track status from the Food and Drug Administration. DIO-902 (levdexketoconazole) is a novel cortisol synthesis inhibitor in development for T2DM. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for T2DM and cardiovascular disease. For more information, visit http://www.diobex.com.


'/>"/>
SOURCE DiObex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
2. Diobex Announces Successful Completion of Phase 2a Trial Of DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
Breaking Medicine News(10 mins):